Alnylam Pharmaceuticals Public Market Comparables

Find the most relevant public market comparables for Alnylam Pharmaceuticals, including EV/Revenue and EV/EBITDA multiples to help you make informed investment decisions.

Company Overview

Alnylam Pharmaceuticals is a leading biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. They pioneer RNAi therapeutics, a revolutionary approach to treating diseases by silencing the genes that cause or contribute to them.

Business Model

Discovery, development, and commercialization of RNAi-based therapeutics. They have a pipeline of investigational medicines and several commercial products on the market.

Target Customers

Patients with genetically defined diseases; healthcare providers; pharmaceutical partners.

Specific Focus

RNA interference (RNAi) therapeutics

Location

Cambridge, Massachusetts

CEO

Yvonne Greenstreet

Industry

Life sciences

Sub Sector

Biopharmaceutical

3yr Revenue Growth

271%

Public Market Comparables

Below are the key valuation metrics for companies similar to Alnylam Pharmaceuticals in the Biotechnology sector. These metrics can help you understand how the market values companies with similar business models and growth profiles.

Looking for a comprehensive compset for Alnylam Pharmaceuticals? Our platform provides detailed analysis of Alnylam Pharmaceuticals's competitive landscape, including financial metrics, growth trends, and market positioning. Get access to the full Alnylam Pharmaceuticals compset by trying our platform today.

EV/Revenue Multiple

Min

0.0x

Median

0.0x

Max

00.0x

Unlock actual values by trying our platform

View Full Details

EV/EBITDA Multiple

Min

00.0x

Median

00.0x

Max

00.0x

Unlock actual values by trying our platform

View Full Details
Screenshot of CompSetFinder showing Alnylam Pharmaceuticals comps with valuation metrics like EV/Revenue, EV/EBITDA, and P/E

Unlock the Full Alnylam Pharmaceuticals Compset

As a leading player in the Life sciences industry within the Biotechnology sector, Alnylam Pharmaceuticals operates in the specialized Biopharmaceutical sub-sector. Understanding how Alnylam Pharmaceuticals compares to its public market comps is essential for accurate valuation and strategic decision-making.

Our comprehensive analysis includes detailed comparables (compsets) featuring similar companies in the Biopharmaceutical space, with complete financial metrics, growth trajectories, and competitive positioning insights that go beyond the surface-level data shown above.

Other Interesting Companies

Capital Rx

HealthcareLife sciences

Capital Rx is a health technology company and benefit administrator advancing our nation's electronic healthcare infrastructure. They provide claim administration and technology solutions for carriers, health plans, TPAs, employer groups, and government entities. As a public benefit corporation and Certified B Corp™, their mission is to materially reduce healthcare costs as a full-service PBM and through the deployment of Judi®, a cloud-native enterprise health platform. Judi unifies pharmacy and medical claims processing, connecting every aspect of the healthcare ecosystem in one efficient, scalable platform.

View comparables

Nurix Therapeutics, Inc.

Biotechnology & DrugsLife sciences

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines to improve treatment options for patients with cancer and inflammatory diseases. Their approach involves modulating cellular protein levels using oral, small molecule therapies.

View comparables

Intra-Cellular Therapies, Inc.

PharmaceuticalsLife sciences

A biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders. The company develops novel drugs for treating diseases of the central nervous system, leveraging proprietary chemistry platforms to develop drugs for neurodegenerative diseases.

View comparables

Get Your Custom Comparable Analysis

Need a more detailed analysis of Alnylam Pharmaceuticals and its public market comparables? Our platform provides comprehensive valuation metrics, growth analysis, and more.

Try CompsetFinder Free